Recombinant Human CBR1 Protein，His

CBR1 (Carbonyl Reductase 1) is an enzyme that belongs to the alcohol dehydrogenase family and plays a crucial role in the metabolism of various carbonyl compounds, including drugs and endogenous metabolites. Its enzymatic activity is pivotal for the reduction of toxic carbonyls into less harmful alcohols, thereby participating in cellular detoxification processes. Moreover, CBR1 has been implicated in the biotransformation of certain pharmacological agents, affecting their efficacy and toxicity. Given its significance in drug metabolism and potential role in disease mechanisms, particularly in cancer and neurodegenerative disorders, understanding the structure-function relationship of CBR1 through recombinant protein studies has become a critical area of research. Advances in recombinant DNA technology allow for the production of CBR1 in sufficient quantities for detailed biochemical and pharmacological analyses. This enables the exploration of its catalytic properties, substrate specificity, and inhibitor interactions, ultimately contributing to the development of CBR1-targeted therapeutic strategies. Furthermore, studying the polymorphisms and expression patterns of CBR1 could provide insights into individual variations in drug responses, thereby enhancing personalized medicine approaches. Overall, the investigation of CBR1 as a recombinant protein holds promise for uncovering its multifaceted roles in metabolism and pharmacology, paving the way for novel therapeutic interventions and improved drug design.